Auhtors: Pantziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP
PMID: 25525463 PMCID: PMC4268104 DOI: 10.3332/ecancer.2014.485
Abstract
Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Keywords: ReDO project; cimetidine; drug repurposing; immunostimulant
Source: https://pubmed.ncbi.nlm.nih.gov/25525463/
Archive: https://archive.is/o5R9M
